Is there a need for viral load testing to assess treatment failure in HIV-infected patients who are about to change to tenofovir-based first-line antiretroviral therapy? Programmatic findings from Myanmar

Aimed to determine prevalence and determinants of ART failure in those on first-line treatment

Abstract

WHO recommends that stavudine is phased out of antiretroviral therapy (ART) programmes and replaced with tenofovir (TDF) for first-line treatment.

This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Thiha N, Chinnakali P, Harries AD, Shwe M, Balathandan TP, Thein Than Tun S, et al. (2016) Is There a Need for Viral Load Testing to Assess Treatment Failure in HIV-Infected Patients Who Are about to Change to Tenofovir-Based First-Line Antiretroviral Therapy? Programmatic Findings from Myanmar. PLoS ONE 11(8): e0160616. doi:10.1371/journal.pone.0160616

Is there a need for viral load testing to assess treatment failure in HIV-infected patients who are about to change to tenofovir-based first-line antiretroviral therapy? Programmatic findings from Myanmar

Published 1 August 2016